Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
NCT ID: NCT01624285
Last Updated: 2023-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2012-07-16
2023-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Two-year recurrence free survival (RFS).
SECONDARY OBJECTIVES:
I. One-year recurrence free survival. II. Overall survival (OS). III. Safety. IV. Impact of drug-drug interactions (i.e. immunosuppression agents). V. Impact of biomarkers (alpha-fetoprotein \[AFP\], protein-induced by vitamin K absence or antagonist II \[PIVKA II\]).
VI. Effects of therapy on wound healing. VII. Impact of hepatitis C viral recurrence.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive sorafenib tosylate orally (PO) twice daily (BID).
ARM II: Patients receive placebo PO BID.
In both arms treatment continues for 24 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (sorafenib tosylate)
Patients receive sorafenib tosylate PO BID.
sorafenib tosylate
Given PO
laboratory biomarker analysis
Correlative studies
Arm II (placebo)
Patients receive placebo PO BID.
placebo
Given PO
laboratory biomarker analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sorafenib tosylate
Given PO
placebo
Given PO
laboratory biomarker analysis
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\* Additionally, the following will be included
\*\* Patients with elevated surrogate markers (AFP \> 500 or PIVKA \> 400) pre transplant and with biopsy proven HCC prior to orthotopic liver transplantation (OLT) or on explant
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* Patients with a life expectancy \> 12 weeks
* Patients must have completed prednisone taper within 6 weeks post OLT
* Patients must be enrolled between 6 to 12 weeks post OLT
* Cadaveric donors only (no living donor liver transplantation \[LDLT\] or donor after cardiac death transplantation \[DCDT\])
* No sorafenib prior to inclusion in the study
* Platelet count \> 50 x 10\^9/L
* Hemoglobin \>= 8.5 g/dL
* Total bilirubin =\< 5 mg/dL
* Alanine transaminase (ALT) and aspartate aminotransferase (AST) =\< 5 x upper limit of normal
* Amylase and lipase =\< 1.5 x the upper limit of normal
* Serum creatinine \< 2 x the upper limit of normal
* Prothrombin time (PT) =\< 6 seconds or international normalized ratio (INR) =\< 2.3
* AFP \> 500 (pre-transplant)
* PIVKA \> 400 (pre-transplant)
* Patient has not received prior anti-angiogenic therapy, systemic targeted agents or systemic chemotherapy
\* Prior surgical resection, chemoembolization or other local therapy prior to transplant is permitted
* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
* Patients (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate
* Patient must be able to swallow and retain oral medication
* Patient must exhibit the ability to understand and willingness to sign a written informed consent regarding the study and alternative treatments
Exclusion Criteria
* Use of T cell depleting agents for prevention or treatment of rejection at any point prior to or after enrollment in the study
* Patient with documented evidence of metastatic disease
* 100% tumor necrosis on explant pathology
* Use of mammalian target of rapamycin (mTOR) inhibitors prior to transplant and as post-transplant immunosuppression
* Use of alemtuzumab
* Living donor liver transplant (LDLT) or donation after cardiac death transplant (DCDT)
* Human immunodeficiency virus (HIV) positive patients
* Hepatitis C virus (HCV) recurrence at the time of randomization
* Use of direct acting antivirals for HCV recurrence
* Requirement of re-transplantation for primary non function
* Uncontrolled hypertension, defined as systolic blood pressure \> 140 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management
* Active or clinically significant cardiac disease including:
* Congestive heart failure - New York Heart Association (NYHA) \> class II
* Coronary artery disease
* Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
* Unstable angina or new-onset angina within 3 months before randomization, or myocardial infarction (MI) within 6 months before randomization
* Clinically active serious infection documented by positive cultures or an incomplete course of treatment for bacteremia or fungemia
* Evidence or history of bleeding diathesis or coagulopathy
* Patients with any pulmonary hemorrhage/bleeding event grade 2 or higher within 4 weeks before randomization
* Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks \[TIAs\]) within 6 months before randomization
* Prior use of raf-kinase inhibitors (sorafenib), vascular endothelial growth factor (VEGF) inhibitors, mitogen-activated protein kinase (MAPK)/extracellular-signal-related kinase (ERK) kinase (MEK) inhibitors, or farnesyl transferase inhibitors
* Patients using cytochrome P450 3A4 (CYP3A4) inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort dexamethasone) at a dose of greater than 16 mg daily, or rifampin and/or rifabutin within 28 days before randomization
* Patients with non-HCC malignancy except those with DCIS (ductal carcinoma in situ), cervical cancer in-situ, basal cell or superficial bladder tumor; patients surviving a cancer that was curatively treated and without evidence of recurrence for more than 3 years before randomization are allowed
* Presence of a non-healing wound, non-healing ulcer, or bone fracture
* Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
* Any malabsorption condition
* Women who are pregnant or breast-feeding
* Inability to comply with the protocol and/or not willing or not available for follow-up assessments
* Patients with fibrolamellar HCC, cholangiocarcinoma, and combined HCC-cholangiocarcinoma
* Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation
* Prior use of any systemic chemotherapy for HCC
* Prior use of systemic investigational agents for HCC
* Prior use of raf-kinase inhibitors (sorafenib), VEGF inhibitors, MEK inhibitors or farnesyl transferase inhibitors
* Use of biologic response modifiers, such as granulocyte colony-stimulating factor (G-CSF), will not be permitted within 3 weeks prior to study entry; G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity, such as febrile neutropenia, when clinically indicated or at the discretion of the investigator; however, they may not be administered to prevent a dose reduction; patients taking chronic erythropoietin are permitted, provided no dose adjustment is undertaken within 1 month prior to randomization or during the study
* Autologous bone marrow transplant or stem cell rescue within four months of start of study drug
* Concomitant treatment with rifampin and St. John's wort
* Concomitant oral mTOR inhibitor treatment
* Use of direct acting antivirals for HCV recurrence
* Use of T-cell depleting agents
* Use of alemtuzumab
* Anticoagulation, as described below, is allowed:
* Vitamin-K antagonists (e.g., warfarin)
\*\* Low dose warfarin (1 mg orally, once daily) with PT-INR =\< 1.5 x ULN is permitted; patients taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes
* Low dose aspirin (=\< 100 mg daily).
* Heparins and heparinoids Use of any other investigational drug
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Busuttil
Role: PRINCIPAL_INVESTIGATOR
Jonsson Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado
Denver, Colorado, United States
Mount Sinai Hospital
Hartford, Connecticut, United States
Lombardi Comprehensive Cancer Center at Georgetown University
Washington D.C., District of Columbia, United States
Emory University
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Lahey Clinic Medical Center
Burlington, Massachusetts, United States
University of Michigan University Hospital
Ann Arbor, Michigan, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
University of Pennsylvania Health System
Cherry Hill, New Jersey, United States
New York University Langone Medical Center
New York, New York, United States
New York Presbyterian-The University Hospital of Columbia and Cornell
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Integris-Baptist Medical
Oklahoma City, Oklahoma, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States
The Methodist Hospital Research Institute
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-00911
Identifier Type: REGISTRY
Identifier Source: secondary_id
11-003311
Identifier Type: -
Identifier Source: org_study_id